Mark Juckett

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Peter L. Greenberg, Richard M. Stone, Aref Al‐Kali et al. · Journal of the National Comprehensive Cancer Network · 2016 · 293 citations

Hematological Malignancy, Oncology, Diagnostic Classification +14

A phase 2 study of vorinostat in acute myeloid leukemia

Élise Schaefer, Arturo Loaiza‐Bonilla, Mark Juckett et al. · Haematologica · 2009 · 117 citations · Full text

Hemolytic uremic syndrome following bone marrow transplantation.

Mark Juckett, Elizabeth H. Perry, Bobbi S Daniels et al. · PubMed · 1991 · 76 citations

Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: Effect of HLA disparity, ABO incompatibility, and method of T-cell depletion

Carolyn A. Keever-Taylor, Christopher Bredeson, Fausto R. Loberiza et al. · Biology of Blood and Marrow Transplantation · 2001 · 66 citations · Full text

Cell Therapy, Agvhd Risk, Immunology +22

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)

Amanda F. Cashen, Mark Juckett, Alcee Jumonville et al. · Annals of Hematology · 2011 · 63 citations

Hematological Malignancy, Chromatin, Oncology +10